Jill Steier | Executive Director, Investor Relations and Corporate Communications |
Mark Iwicki | Chairman and Chief Executive Officer |
Todd Bazemore | President and Chief Operating Officer |
Kim Brazzell | Head of R&D and Chief Medical Officer |
Mary Reumuth | Chief Financial Officer |
Christopher Neyor | J.P. Morgan |
Francois Brisebois | Oppenheimer & Co. |
Andreas Argyrides | Wedbush Securities |
Good morning and welcome to Kala Pharmaceuticals Conference Call to Review its Fourth Quarter 2022 Financial Results. At this time, all participants are in a listen-only mode.
Following management's prepared remarks, a Q&A session will be held.
As a reminder, this call is being recorded. I would like to turn the call over to Jill Steier, Executive Director, Investor Relations and Corporate Communications for Kala Pharmaceuticals.